Anifrolumab in Systemic Lupus Erythematosus with Renal Involvement: National Multicenter Registry in Clinical Practice (ACR Convergence 2025) - Sep 15, 2025 - Abstract #1547; Pres time: Oct 27, 2025; 10:30 AM - 12:30 PM; Location: Hall F1; In Person; "All of them had received belimumab, and 15 mycophenolate mofetil. The standard ANI regimen was 300 mg every 4 weeks, except in two patients who received loading doses (900 mg/4 weeks for 3 months, then 300 mg/4 weeks).In addition to corticosteroids, ANI was administered concomitantly with antimalarials (n=16), mycophenolate mofetil (n=11), tacrolimus (n=4), azathioprine (n=2), methotrexate (n=1), and voclosporin (n=1)...The prednisone dose was decreased from 9.2±7.9 mg/day to 3.3±2 mg/day (p= 0.1). To our knowledge, this is the first real-life study of ANI in LN. To our knowledge, this is the first real-life study of ANI in LN. In refractory patients to multiple immunosuppressive therapies, we observed a rapid and maintained effectiveness in SLE activity and renal manifestations, with a good safety profile. These preliminary data should be confirmed in clinical trials."
Clinical • Dermatology • Glomerulonephritis • Herpes Zoster • Hidradenitis Suppurativa • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease • Systemic Lupus Erythematosus • Varicella Zoster
|
|
Vanesa Calvo-Río1; Carmen Secada-Gómez1; Blanca Garcia-Magallon2; Deseada Palma-Sanchez3; Andrea García-Valle4; Irati Urionaguena Onaindia5; Adrián Mayo-Juanatey6; Paúl Hernández Velasco7; GUILLERMO GONZALEZ ARRIBAS8; Ana Pareja-Martínez9; Montserrat Corteguera10; Guillen Sada Urmeneta11; Paz Collado Ramos12; Jose Luis Tandaipan13; Juan Roberto Miguelez Sanchez14; Ricardo Blanco1
|